Research & Development

Investigational Therapeutic for
Episodic Cardiovascular Conditions

Etripamil Clinical Pipeline

AREA OF FOCUS PRECLINICAL PHASE I PHASE II PHASE III ANTICIPATED MILESTONES PHASE

Rapid conversion to sinus rhythm

Rapid conversion to sinus rhythm Top-line Phase 3 results in 1H 2020 PHASE III

Temporary control of rapid ventricular rate

Temporary control of rapid ventricular rate Initiate Phase 2 trial in 2H 2019 RESEARCH

Acute relief of angina symptoms

Acute relief of angina symptoms Initiate Phase 2 trial in 2020 RESEARCH

There are no FDA-approved, self-administered, pharmaceutical treatment options to stop PSVT or atrial fibrillation, and limited to no options for patients experiencing acute anginal symptoms. Milestone’s lead investigational candidate, etripamil, aims to address a significant unmet medical need for self-administered products to terminate these episodes in the outpatient setting.

Etripamil is a proprietary, small molecule, new chemical entity that was conceived, discovered, and optimized by Milestone. Etripamil is currently being tested in Phase 3 trials for PSVT. It is administered intranasally to allow for rapid systemic drug delivery. Etripamil is designed to be fast-acting with a short half-life, measured in minutes. Etripamil is not currently approved for the treatment of PSVT or for any other indication anywhere in the world.